FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs
The United States Food and Drug Administration has approved NUMELVI™ (atinvicitinib tablets), a new treatment for itch associated with allergic dermatitis in dogs, developed by Merck Animal Health. The company says the medication is the first and only second-generation Janus kinase (JAK) inhibitor approved in the United States for this indication.
Merck Animal Health Receives Positive Opinion from EU CVMP for Numelvi Tablets for Dogs
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., has announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for Numelvi (atinvicitinib) tablets for dogs. This marks an important step toward the availability of Numelvi in the European Union.